On 3/25/25, Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock suffered a major decline of -14.0%, closing at $5.60. Moreover, trading volume in this decline was exceptionally high at 266% of normal. The stock has declined -8.8% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Karyopharm Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment